Last Updated: 21 Jul 2025
Source: Statifacts
Neurology Market (By Therapeutic Application: Neurodiagnostic Devices, Neurostimulation Devices, Others; By Region: North America, Europe, Asia Pacific, LAMEA) Industry Size, Share, Growth, Trends 2025 to 2034
The global neurology market size surpassed USD 3.85 million in 2024 and is predicted to reach around USD 9.5 million by 2034, registering a CAGR of 9.46% from 2025 to 2034. The neurology market is expanding rapidly, driven by a growing prevalence of neurological conditions like Alzheimer’s. Parkinson’s, epilepsy, and stroke, which fuel demand for advanced diagnostics the therapies. Technological breakthroughs such as neuroimaging innovations, neurostimulation, gene therapy, and biomarkers are enabling earlier detection and more personalized treatments.
The neurology market encompasses medical technologies and devices used in diagnostics and treating neurological disorders such as Alzheimer’s, epilepsy, Parkinson’s disease, and stroke. It includes neurostimulation devices, neurodiagnostics tools, and other neurotherapeutic solutions. These are widely used in hospitals, clinics, diagnostic centres, and specialized neuroscience institutions. The technology supports applications across neurosurgery, neurorehabilitation, pain management, and cognitive monitoring. With the increasing prevalence of neurological diseases and a growing geriatric population, demand has significantly surged. The sector also benefits from rising investment in research and development and a shift toward non-invasive neuromodulator therapies.
Artificial intelligence is revolutionizing the neurology market by improving clinical decision-making, early diagnosis, and personalized treatment strategies. AI systems are being used to analyse vast volumes of brain imaging data such as MRIs and EEGs, improving the speed and accuracy of neurological assessments. These technologies are for epilepsy. Additionally, AI-driven tools support neurorehabilitation, allowing for more adaptive and patient-specific recovery programs. This integration is streamlining healthcare delivery, expanding access to timely neurological care.
Neurological disorders now affect over 40% of the global population, with approximately 3.4 billion people experiencing related health issues in 2021. These conditions accounted for nearly 11 million deaths that year. The increasing toll of conditions such as stroke, dementia, migraines, and diabetic neuropathy, fuelled by demographic shifts like population growth and aging, has intensified demand for advanced diagnostics, treatments, and rehabilitative care, driving market growth significantly.
Parkinson’s disease is currently the fastest-growing neurological condition, with cases predicted to rise by over 74% from 1990 to 2016, and projected to exceed 12 million individuals by 2040. This sharp escalation is driven by global aging trends, environmental toxins, and genetic interactions. The expanding patient population is prompting heightened development and adoption of neurotherapeutic solutions, from precision diagnostics to novel neurostimulation therapies.
One of the most significant barriers to market growth is the steep cost associated with cutting-edge neurology devices such as high-field MRIs, neuromodulation systems, and robotic surgical tools. These technologies often require substantial capital investment and ongoing maintenance, which many hospitals and clinics, particularly in low and middle-income regions, cannot afford. As a result, this restricts the availability and adoption of state-of-the-art neurological care, leading to disparities in patient access and hindering broader market penetration.
Manufacturers and providers also face lengthy. Complex regulatory approval pathways, especially for class 3 neuro devices and AI-integrated systems, are leading to delayed market entry and higher development costs. Compounding this issue is the inconsistent or limited reimbursement from healthcare payers, particularly for novel neuroethologies. This creates financial uncertainty for both adopters and developers, often discouraging investment and slowing the deployment of innovative neurology solutions.
The extensive rollout of tele-neurology, especially tele stroke services, has enabled remote to neurologists, dramatically improving acute stroke treatment. For instance, tele-neurology pre-notification systems assured that 50.4% of patients received. Moreover, neurologists reported conducting around 36% of weekly patient visits via telehealth, with 98% adoption among practitioners, significantly reducing the gap in specialist reach and improving chronic care management. This digital expansion offers scalable solutions for underserved, rural, and mobility-limited populations, driving broader market growth.
Cutting-edge advancements in brain computer interfaces and AI-enhanced neural implants are presenting novel therapeutic pathways. Research on attention-based neural interfaces shows superior EEG signal decoding using transformer models, while recent human trials demonstrate high-performance finger control BCIs that decode four degrees of freedom to operate devices like virtual quadcopters. These developments could revolutionize care for individuals with paralysis, enabling intuitive control of prosthetics and fostering scalable, real-world neural assistive technologies.
By therapeutic, the neurostimulation devices segment dominated the neurology market in 2024 and is expected to sustain this position in the coming years. These devices, including Deep Brain Stimulators and Vagus Nerve Stimulators, have shown proven effectiveness in treating chronic neurological disorders such as epilepsy, Parkinson’s disease, and chronic pain. The non-invasive nature and long-term relief provided by these devices have made them a preferred therapeutic solution among healthcare providers and patients. Additionally, increased FDA approvals and adoption in emerging economies have significantly widened their accessibility. As neurological conditions continue to rise globally, the demand for advanced neurostimulation tools remains strong. The segment’s sustained dominance stems from its clinical efficacy and continued innovation in device technology.
By therapeutic application, TENS Units are projected to grow at the fastest rate in the neurology market between 2025 and 2034. These devices are gaining popularity for their role in pain management and rehabilitation therapy for various neurological and musculoskeletal disorders. Their affordability, portability, and increasing acceptance in both clinical and home-based care environments make them attractive to a wide demographic. Furthermore, growing awareness about non-opioid alternatives for chronic pain treatment is propelling their market growth. Technological advancements, such as wireless connectivity and app-based control features, are further improving patient adherence and experience. The combination of clinical relevance and patient friendly drives this segment’s rapid growth.
The other segment, though not the largest or fastest growing, underwent notable growth in the neurology market during 2024. This segment encompasses merging therapies and diagnostic devices. It includes niche therapeutic innovations and adjunctive therapies used in specialized neurological care. The growth in this segment is largely attributed to research advancements and experimental clinical practices being adopted in tertiary care centres. As precision medicine and individualized neurological treatments gain momentum, this segment is likely to become more prominent. It reflects an expanding and diversifying market responding to unmet needs in neurology.
North America led the neurology devices market in 2024, capturing around 40.7% of global revenue. This dominance stems from its sophisticated healthcare infrastructure, extensive reimbursement frameworks, and a strong pool of specialized neurologists. Rapid adoption of advanced neuroimaging, neurostimulation, and robotic-assisted technologies. Canada’s single-payer system supports nationwide trials of devices like closed-loop stimulators, while the U.S. benefits from leading electronics and brain research investments.
The Asia Pacific region is forecasted to grow at the fastest CAGR in the neurology market, driven by strong government initiatives and rapidly improving healthcare infrastructure. China’s active development of brain computer interfaces and Japan’s advanced tele-neurology pilots highlight regional tech leadership. India is reporting double-digit growth in device adoption, especially for endovascular and diagnostic technologies. Public-private investments are boosting equipment procurement and domestic manufacturing, while rising neurological disease prevalence in aging populations fuels ongoing expansion.
The neurology devices market is highly concentrates, dominated by a few large players with global reach and extensive research and extensive research and development capabilities.
Medtronic is providing devices for neuroscience, cardiovascular, diabetes, and surgical sectors. In neurology, its product line includes implantable neurostimulators, neurovascular stents, and diagnostic hardware. The company's research and development pipeline includes advanced AI-assisted neuroimaging, remote monitoring, and intelligent stimulators aimed at personalized, real-time therapy optimization.
Boston Scientific develops medical devices for interventional cardiology, neuromodulation, oncology, and urology. In neurology, key offerings include deep brain stimulation systems and pain management stimulators. Recent breakthroughs include US FDA approval of Vercise Neural, Navigator 5 software, and strong growth in its electrophysiology segment, with a 72% rise in Farapulse adoption.
Abbott operates globally across diagnostics, medical devices, nutrition, and pharmacies. Its neuromodulation portfolio features deep brain stimulation systems and spinal cord stimulators. The Infinity DBS system integrates advanced directional leads with eight contact points targeting essential tremor.
| Regions | Shares (%) |
| North America | 38% |
| Asia Pacific | 25% |
| Europe | 27% |
| LAMEA | 10% |
| Segments | Shares (%) |
| Neurodiagnostic Devices | 40 % |
| Neurostimulation Devices | 35 % |
| Others | 25 % |
